DENTSPLY SIRONA Q3 Earnings Call Highlights

DENTSPLY SIRONA reported Q3 earnings with a $39M pretax accounting benefit, not expected to recur. Operating cash flow declined to $32M. Wellspect Healthcare revenue rose 10%, while dental segments saw declines. The company repurchased 1.2M shares and plans $120M in savings for 2026. Management expects continued investment in growth areas.

Original reporting
Published Nov 6, 2026, 11:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 11:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
DENTSPLY SIRONA Q3 Earnings Call Highlights — source image
Decision brief

The 30-second read

$XRAYBearishMed
01

Why it matters

The earnings miss and cash‑flow decline are likely to weigh on the stock in the short term, though the buyback and settlement may provide some support.

02

Market read

Primary earnings release for a mid‑cap healthcare equipment company; relevance driven by guidance change and litigation settlement.

03

What to watch

Potential upside from the proposed Byte litigation settlement and the aggressive MIS sales‑force expansion could improve future margins.

Relevance 8/10Novelty 7/10Timing: after‑hours release

Background

Dentsply Sirona (NASDAQ:XRAY) reported Q3 results with mixed performance across its segments, highlighted a one‑time accounting benefit, updated guidance, and disclosed a settlement memorandum for the Byte securities litigation.

Company-level read

Ticker impact

$XRAYBearishHigh confidence
Context

Q3 earnings call disclosed a $39M pretax accounting benefit, updated earnings guidance, a $30M after‑tax benefit, cash flow decline and a $120M savings target, plus a proposed settlement for the Byte securities litigation.

Expected impact

likely modest downside as market prices in weaker cash flow and guidance, partially offset by the one‑time accounting benefit and share repurchase.

Evidence & confidence

Guidance and cash flow are core fundamentals; the benefit is non‑recurring, so investors will focus on the lower outlook.

Market effects

Dental equipment and consumables sector may see slight pressure as Dentsply Sirona signals weaker demand in several regions.

EMEA and Middle East markets could be affected by the noted underperformance.

Limited to investors tracking healthcare equipment and dental‑technology stocks.

Counterpoint

The accounting benefit and ongoing buyback could be viewed as a floor, suggesting the stock may be undervalued after the earnings dip.

Key entities

  • Dentsply Sirona

    Global manufacturer of professional dental products and technologies.

  • Byte

    Entity involved in securities litigation with Dentsply Sirona.

Related articles

$XRAYHighAI 8/10

XRAY Q3 2026 deep dive: revenue shortfall and guidance cut amid dental market headwinds

XRAY reported Q3 2026 revenue of $836M, missing estimates by 2.7%, with adjusted EPS of $0.29, missing by 6.2%. The company cut full-year revenue guidance to $3.5B and adjusted EPS to $1.25. Growth in Wellspect Healthcare and U.S. dental segments was offset by inventory reductions and market challenges in EMEA and the Middle East. Management highlighted cost-saving initiatives and investments in sales and education.

MedAI 8/10

Dentsply Sirona Lowers 2026 EPS Outlook After Third-Quarter Sales Slide

Dentsply Sirona (XRAY) lowered its 2026 adjusted EPS outlook to $1.20-$1.30 after Q3 sales fell 7.6% to $836M and adjusted EPS dropped 29.4% to $0.29. The company expects $3.5B in 2026 sales, down from its prior $3.5B-$3.6B forecast. Q3 net loss was $2M, improved from a $427M loss in Q3 2025. Sales varied across business segments, with Wellspect Healthcare up 10.1%.

HighAI 8/10

DENTSPLY (XRAY) Q3 2026 Earnings Call Transcript

DENTSPLY SIRONA (XRAY) reported Q3 2026 revenue of $836M, down 7.6%, and adjusted EPS of $0.29. The company lowered its full-year guidance to $3.5B in sales and $1.20-$1.30 in adjusted EPS, citing business pressures and investment in growth initiatives. Wellspect Healthcare saw record sales growth, while other segments faced challenges.

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) stock trades down, here is why

Dentsply Sirona (XRAY) shares fell 7% after reporting a Q3 2026 GAAP loss of $0.01 per share and lowering its full-year outlook. Net sales were $836M, missing estimates. The company now expects 2026 net sales of $3.5B and adjusted EPS of $1.20-$1.30. Shares are down 17.4% YTD and 36.6% below their 52-week high.

$XRAYMed

BofA cuts Dentsply Sirona stock price target on guidance reset

BofA Securities reduced its price target for Dentsply Sirona (XRAY) to $14 from $17, citing disappointing Q3 results and a revised 2026 EPS guidance of $1.10. The stock trades near its 52-week low at $8.14. BofA noted positive developments in some segments but expects growth stabilization over time. XRAY's Q3 earnings and revenue missed estimates, leading to a stock price drop.